Sun Pharma Q1 FY27 Results: Net Profit Rises 27% to ₹2,895 Crore
By Kaushik Brahmakshatriya
Published On 01 August 2026.
Sun Pharma Q1 FY27 Results
India’s largest drugmaker has posted a strong quarter. The Sun Pharma Q1 FY27 Results reveal a healthy jump in profitability along with steady double-digit revenue growth, driven by strong domestic demand and expanding innovative medicine sales, even as the US generics business continued to face pricing pressure during the period.
Sun Pharma Q1 FY27: Financial Performance at a Glance
Sun Pharmaceutical Industries reported consolidated net profit attributable to owners of ₹2,894.79 crore for the quarter ended June 30, 2026, a rise of 27% compared to ₹2,278.63 crore in the same quarter last year. Adjusted net profit, which excludes exceptional items, grew a more modest 3.1% year-on-year to ₹3,089.4 crore, indicating that the reported profit jump was partly aided by lower one-off charges than the year-ago period
Consolidated revenue from operations came in at ₹15,183.55 crore, up 10.1% from ₹13,786.07 crore in Q1 FY26. Total income for the quarter stood at ₹16,023.50 crore. EBITDA grew 2.7% to ₹4,417.70 crore from ₹4,301.70 crore, while basic and diluted earnings per share rose to ₹12.1 from ₹9.5 a year earlier. The company also booked exceptional items worth ₹204.09 crore, largely tied to acquisition costs for its pending Organon & Co. deal.
Business Divisions and R&D Highlights
Growth during the quarter was powered mainly by India and the innovative medicines portfolio, while the US generics segment stayed under pressure. Research and development spending stood at ₹826.35 crore, roughly 5.4% of sales, with nearly a third of that allocated toward innovative medicines research. In the US market, Sun Pharma held 558 approved abbreviated new drug applications, with 119 more awaiting FDA clearance, including 28 tentative approvals. The company filed three new ANDAs and received six approvals during the quarter.
Management Insights and Future Outlook
Chairman Dilip Shanghvi noted that regulatory filings for the Organon acquisition have been completed across multiple markets, with approvals already secured in some regions, and that the deal is on track to close in the fourth quarter of FY27. CFO Jayashree Satagopan reiterated guidance of high single-digit revenue growth for the full year, while flagging that acquisition-related expenses will continue over the coming quarters.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
| Net Profit | ₹2,894.79 crore | ₹2,278.63 crore | +27% |
| Revenue from Operations | ₹15,183.55 crore | ₹13,786.07 crore | +10.1% |
| EBITDA | ₹4,417.70 crore | ₹13,786.07 crore | +2.7% |
| EPS (Basic & Diluted) | ₹12.1 | ₹4,301.70 crore | +27.4% |
| R&D Expense | ₹826.35 crore | — | 5.4% of sales |
FAQ (Frequently Asked Questions)
| Question | Answer |
| What was Sun Pharma’s net profit in Q1 FY27? | ₹2,894.79 crore, up 27% year-on-year. |
| How much did Sun Pharma’s revenue grow in Q1 FY27? | Revenue rose 10.1% to ₹15,183.55 crore. |
| What was Sun Pharma’s EPS in Q1 FY27? | Basic and diluted EPS stood at ₹12.1. |
| When will the Organon acquisition close? | Management expects it to close in Q4 FY27. |
| Is the US generics business growing? | No, it remained under pressure while India and innovative medicines led growth. |
Conclusion
Overall, the Sun Pharma Q1 FY27 Results paint a picture of steady, broad-based growth led by domestic formulations and the innovative medicines pipeline. While headline profit growth looks strong, adjusted profit growth was more modest, and US generics remain a soft spot. With the Organon deal nearing completion and R&D investment continuing, the Sun Pharma Q1 FY27 Results set a cautiously positive tone for the rest of FY27, though investors should track integration costs and US pricing trends closely in the Sun Pharma Q1 FY27 Results coverage ahead.
Disclaimer :
This content is for informational and educational purposes only and is not investment advice. Please consult a financial advisor before making investment decisions
